These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62 related articles for article (PubMed ID: 1580549)
1. Inhibition of tumor growth by the intralesional administration of interleukin-3 into mice implanted with solid tumors. Sasaki H; Schmitt DA; Hayashi Y; Pollard RB; Suzuki F Anticancer Res; 1992; 12(2):313-5. PubMed ID: 1580549 [TBL] [Abstract][Full Text] [Related]
2. Induction of interleukin 3 and tumor resistance by SSM, a cancer immunotherapeutic agent extracted from Mycobacterium tuberculosis. Sasaki H; Schmitt D; Hayashi Y; Pollard RB; Suzuki F Cancer Res; 1990 Jul; 50(13):4032-7. PubMed ID: 2354453 [TBL] [Abstract][Full Text] [Related]
3. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity. Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715 [TBL] [Abstract][Full Text] [Related]
4. Antitumor mechanisms of Z-100, an immunomodulatory arabinomannan extracted from Mycobacterium tuberculosis: the importance of lymphocytes infiltrated into tumor sites. Sasaki H; Schmitt D; Hayashi Y; Pollard RB; Suzuki F Nat Immun; 1993; 12(2):104-12. PubMed ID: 8318815 [TBL] [Abstract][Full Text] [Related]
5. Distinct antitumor mechanisms of recombinant interleukin-2 on recombinant interleukin-2-activated killer-sensitive and -resistant murine tumors. Maekawa R; Kitagawa T; Koizumi K; Sato K; Homma M J Biol Response Mod; 1989 Dec; 8(6):676-90. PubMed ID: 2600605 [TBL] [Abstract][Full Text] [Related]
6. Recombinant human tumor necrosis factor-alpha: evidence of an indirect mode of antitumor activity. Manda T; Shimomura K; Mukumoto S; Kobayashi K; Mizota T; Hirai O; Matsumoto S; Oku T; Nishigaki F; Mori J Cancer Res; 1987 Jul; 47(14):3707-11. PubMed ID: 3594435 [TBL] [Abstract][Full Text] [Related]
7. [Antitumor effect of Cepharanthin in the double grafted tumor system]. Ebina T; Ishikawa K; Murata K Gan To Kagaku Ryoho; 1990 Jun; 17(6):1165-71. PubMed ID: 2350192 [TBL] [Abstract][Full Text] [Related]
8. Marked reduction of subcutaneous tumor growth by intraperitoneal administration of recombinant human interleukin 2 with a cell accumulator, proteose-peptone, in mice. Tanida S; Uchida H; Taniguchi K; Nomoto K Cancer Res; 1989 Jan; 49(2):284-8. PubMed ID: 2783379 [TBL] [Abstract][Full Text] [Related]
9. Antitumor effects of recombinant human interleukin 1 alpha in RIF-1 and Panc02 solid tumors. Braunschweiger PG; Johnson CS; Kumar N; Ord V; Furmanski P Cancer Res; 1988 Nov; 48(21):6011-6. PubMed ID: 3262418 [TBL] [Abstract][Full Text] [Related]
10. [Antitumor Effector mechanism of plant alkaloid preparation, cepharanthin, by intratumoral administration]. Ebina T; Murata K Gan To Kagaku Ryoho; 1991 Aug; 18(11):1812-6. PubMed ID: 1877822 [TBL] [Abstract][Full Text] [Related]
11. Tumor growth suppression by a mouse/human chimeric anti-CEA antibody and lymphokine-activated killer cells in vitro and in SCID mouse xenograft model. Senba T; Kuroki M; Arakawa F; Yamamoto T; Kuwahara M; Haruno M; Ikeda S; Matsuoka Y Anticancer Res; 1998; 18(1A):17-24. PubMed ID: 9568050 [TBL] [Abstract][Full Text] [Related]
12. Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation. Kim JA; Averbook BJ; Chambers K; Rothchild K; Kjaergaard J; Papay R; Shu S Cancer Res; 2001 Mar; 61(5):2031-7. PubMed ID: 11280763 [TBL] [Abstract][Full Text] [Related]
13. Multiple roles of interferon-gamma in the mediation of interleukin 12-induced tumor regression. Ogawa M; Yu WG; Umehara K; Iwasaki M; Wijesuriya R; Tsujimura T; Kubo T; Fujiwara H; Hamaoka T Cancer Res; 1998 Jun; 58(11):2426-32. PubMed ID: 9622084 [TBL] [Abstract][Full Text] [Related]
14. Synergism between IFN-gamma and IL-1 alpha/beta in growth inhibition of an allografted tumor. Takikawa O; Oku T; Yasui H; Yoshida R J Immunol; 1993 Aug; 151(4):2070-6. PubMed ID: 8345196 [TBL] [Abstract][Full Text] [Related]
15. Interleukin 18 induces the sequential activation of natural killer cells and cytotoxic T lymphocytes to protect syngeneic mice from transplantation with Meth A sarcoma. Micallef MJ; Tanimoto T; Kohno K; Ikeda M; Kurimoto M Cancer Res; 1997 Oct; 57(20):4557-63. PubMed ID: 9377569 [TBL] [Abstract][Full Text] [Related]
16. [Antitumor effect of a novel antitumor compound, NC-190, in the double grafted tumor system]. Ebina T; Shishido K; Murata K Gan To Kagaku Ryoho; 1990 Jul; 17(7):1345-50. PubMed ID: 2369138 [TBL] [Abstract][Full Text] [Related]
17. Effect of continuous administration of interleukin 2 on active specific chemoimmunotherapy with extracted tumor-specific transplantation antigen and cyclophosphamide. Naito K; Pellis NR; Kahan BD Cancer Res; 1988 Jan; 48(1):101-8. PubMed ID: 3257158 [TBL] [Abstract][Full Text] [Related]
18. Differential antitumor effects of administration of recombinant IL-18 or recombinant IL-12 are mediated primarily by Fas-Fas ligand- and perforin-induced tumor apoptosis, respectively. Hashimoto W; Osaki T; Okamura H; Robbins PD; Kurimoto M; Nagata S; Lotze MT; Tahara H J Immunol; 1999 Jul; 163(2):583-9. PubMed ID: 10395644 [TBL] [Abstract][Full Text] [Related]
19. Inhibition of tumor growth and metastasis by an immunoneutralizing monoclonal antibody to human vascular endothelial growth factor/vascular permeability factor121. Asano M; Yukita A; Matsumoto T; Kondo S; Suzuki H Cancer Res; 1995 Nov; 55(22):5296-301. PubMed ID: 7585591 [TBL] [Abstract][Full Text] [Related]
20. Antitumor effect of interleukin 7 in combination with local hyperthermia in mice bearing B16a melanoma cells. Wu B; Shen RN; Wang WX; Broxmeyer HE; Lu L Stem Cells; 1993 Sep; 11(5):412-21. PubMed ID: 8241952 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]